1. PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) Authors: Belada, D.; Kopeckova, K.; Bergua Burgues, J. M.; Stevens, D.; Nowakowski, G. S.; Waldron-Lynch, M.; Hadar, N.; Weirather, J.; Lässig, C.; Blair, D.; Dreyling, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1981 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) Authors: Vitolo, U.; Nowakowski, G. S.; Burke, J. M.; Fox, C. P.; Trneny, M.; Chiappella, A.; Waldron-Lynch, M.; Hadar, N.; Pachori, A.; Lenz, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies. (October 2022) Authors: Kindler, H.; Harvey, R.D.; Duska, L.R.; Gandhi, L.; Sullivan, R.J.; Gastinne, T.; Kwiatek, M.; García-Sancho, A.M.; Hadar, N.; Kann, L.; Faulhaber, N.; Drescher, C. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗